EZH2 and breast neoplasm: In the present study, we showed that pharmacological inhibition of EZH2 using a novel EZH2 inhibitor ZLD1039, reduced cell proliferation, induced breast cancer cell apoptosis, and led to the regression of three established breast tumor xenografts in mice with excellent tolerance.